Understanding the regulatory mechanisms of bone homeostasis has led to the discoveries of the receptor activator of the nuclear factor kappa B ligand (RANKL) as a therapeutic target for osteoporosis and bone erosion, Sclerostin as a target for osteogenesis-promoting drugs, and the mechanism underlying postmenopausal osteoporosis development [9,10,11]. This evidence concerns the gene TNFSF11 and osteoporosis.